The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Open accessAbstract
Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered. However, its favorable skeletal effects reverse quickly upon its discontinuation, because of a vast increase of osteoclast number and activity, which leads to a subsequent profound increase of bone turnover above pre-treatment values, a phenomenon commonly described as “rebound phenomenon”. More importantly, most patients experience rapid, profound bone loss due to this burst of bone resorption that may lead in a minority of these patients to occurrence of fractures, especially multiple vertebral fractures. Therefore, subsequent antiresorptive treatment is mandatory, although the optimal regimen is yet to be clarified. In the present review, we outline what is currently known regarding the negative effects of denosumab discontinuation on different aspects of bone status, the factors that may affect them, and strategies to prevent them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990 · cited 1×
“Estrogen withdrawal [13] during menopause or treatment with aromatase inhibitors (AIs), rheumatoid arthritis [14,15], and glucocorticoids [16] are common and characteristic conditions that can lead to an increase in RANKL secretion by osteocytes and osteoblasts, enhancing activation of osteoclast precursors and mature…”
BackgroundXiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., Bonewald, L., Manolagas, S. C., & O’Brien, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138189 · Cited by 323
Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21896 · Cited by 182
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., & Zanchetta, J. R. (2018) · Osteoporosis International · doi:10.1007/s00198-017-4242-6 · Cited by 119
Cited by
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 282
Regulation of TNF-Induced Osteoclast Differentiation
Yao, Z., Getting, S. J., & Locke, I. C. (2021) · Cells · doi:10.3390/cells11010132 · Cited by 280
“One special concern for denosumab is that its discontinuation is associated with a subsequent profound increase of bone turnover above pre-treatment values due to a substantial increase in OC number and activity, resulting in a risk of multiple vertebral fractures [24,25].”
Background
Metadata
- Authors
- Anastasilakis, A. D., Makras, P., Yavropoulou, M. P., Tabacco, G., Naciu, A. M., & Palermo, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-01-04
- Volume
- 10
- Issue
- 1
- Pages
- 152
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3120383256
- Cited by
- 200
- References
- 6
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. https://app.cochat.ai/papers/10.3390/jcm10010152
- The paper
- Anastasilakis, A. D., Makras, P., Yavropoulou, M. P., Tabacco, G., Naciu, A. M., & Palermo, A. (2021). Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10010152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.